Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
Chandrakala ShanmukhaiahFarah JijinaS KannanNanda G PaiBipin KulkarniSantosh V KhubaMadiha ShaikhAditi JoshiRajesh PhataleShashikant AptePublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)
In conclusion, this review supports the safety and efficacy of emicizumab in type 3 VWD patients with or without alloantibodies. Further large studies are required to confirm the safety and efficacy of emicizumab in VWD.
Keyphrases